Fabry Disease (X-linked lysosomal storage disease). research hub

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease.

This study is testing a new gene therapy, ST-920, for men with Fabry disease. It's an early-stage trial looking at how safe the treatment is and if it helps by correcting the faulty gene causing the condition. Researchers will carefully check participants' health.